Drug manufacturer Novo Nordisk late yesterday appealed a federal district judge’s Nov. 5 joint ruling in its and fellow manufacturer Sanofi’s 340B contract pharmacy lawsuits. Sanofi filed its appeal earlier yesterday.
Novo Nordisk’s notice of appeal, like Sanofi’s, is
…
Drug manufacturer Sanofi today gave notice that it is appealing a federal district judge’s Nov. 5 orders and opinions in its 340B contract pharmacy lawsuit.
Sanofi’s one-sentence Nov. 19 notification to the federal government defendants and U.S. Chief District
…
The U.S. Health Resources and Services Administration (HRSA) yesterday asked the White House to review and approve a 340B administrative dispute resolution (ADR) proposed regulation for publication in the Federal Register.
The proposed rule’s purpose is unknown. HRSA published a
…
Drug manufacturer Lilly’s appeal of a federal district judge’s ruling late last month in the company’s 340B contract pharmacy lawsuit has hit a procedural snag.
In an unsigned pair of orders on Tuesday, the federal appeals court in Chicago questioned
…
A Kansas Republican congressman said on Capitol Hill yesterday that pharmacy benefit managers (PBMs) are taking away health centers and other safety net providers’ 340B savings and driving up their costs.
340B health centers and other providers “are reporting that
…
The U.S. Health Resources and Services Administration (HRSA) has reconfirmed that it is auditing 340B covered entities for program compliance both remotely and in-person this fiscal year.
HRSA told 340B Report in mid-September that in October it would resume
…
The Biden administration said yesterday it is delaying by six months the effective date of a Trump administration final rule to let drug manufacturers report multiple best prices on their products if states opt to participate in value-based purchasing (VBP)
…
The federal fine for overcharging a 340B covered entity just went up from $5,883.00 to $5,953.00 per each instance of overcharging.
The U.S. Health and Human Services Department (HHS) Office of Inspector General (OIG) posted its annual inflation adjustments to
…
U.S. manufacturers of insulin and diabetes-related treatments asked a federal judge on Friday to dismiss two health centers’ antitrust class action over the companies’ denials of 340B pricing when covered entities use contract pharmacies.
In a Nov. 11 joint
…*Sign up for news summaries and alerts from 340B Report